Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.
A fifth-generation cephalosporin with coverage against key causative pathogens in children with cSSTI, including MRSA, and CAP, including penicillin susceptible strains of S. pneumoniae1,2
Zinforo has relatively low protein binding (<20%), and using data comparing protein binding with rate of penetration to the site of infection, is predicted to have a rapid penetration rate3,4
A safety and tolerability profile consistent with comparator therapies in clinical studies‡§5-8 and a similar safety profile in the paediatric population to that observed in adults.II
Approved to treat neonates and infants <2 months of age with a proven clinical response in paediatric patients with cSSTI and CAP.9,10
Zinforo 600 mg powder for concentrate for solution for infusion
Explore the outcomes of the Zinforo Phase III clinical trials in adult patients with CAP and cSSTI
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020